Latest / Oncology Data Advisor
From Glass Slides to AI: How Digital Pathology and MRD Testing Are Transforming Cancer Care With Osama Khan, MD, and Waqas Haque, MD, MPH
In this episode of the Exploring Artificial Intelligence (AI) in Oncology series, Waqas Haque, MD, MPH, Hematology/Oncology Fellow at the University of Chicago, speaks with Osama Khan, MD, Staff Pathologist at Natera, a cell-free DNA (cfDNA) technology company that aims to make personalized genetic testing and diagnostics part of the standard of care. Dr. Khan shares insights into how digital pathology and emerging technologies like AI and measurable residual disease (MRD) testing are revolutionizing oncology, driving precision medicine, and enhancing patient care. Learn more at…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.